Form 4: Avid Bioservices Executive Exercises Stock Options
SEC Form 4 Filing
Mark R. Ziebell, V.P. and General Counsel of Avid Bioservices, Inc., reports the vesting and conversion of restricted stock units into common stock.
Summary
- On April 9, 2024, Mark R. Ziebell, V.P. and General Counsel of Avid Bioservices, Inc. (CDMO), converted restricted stock units (RSUs) into common stock.
- Ziebell converted 696 RSUs granted on July 9, 2021, 1,261 RSUs granted on July 9, 2022, and 1,251 RSUs granted on July 9, 2023.
- These transactions increased Ziebell's direct ownership of Avid Bioservices common stock to 66,477 shares, while decreasing his holdings of RSUs to 34,866.
- The RSUs vest in equal quarterly installments over four years from their respective grant dates, contingent upon Ziebell's continued service to the company.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The filing reflects standard executive compensation practices and insider confidence, but doesn't contain information that would drastically alter investor perception.
Positives
- The vesting of RSUs is part of Ziebell's compensation package and aligns his interests with those of the shareholders.
- The exercise of options and holding of stock demonstrates confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding insider transactions and aligns with regulatory requirements.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology and contract development and manufacturing (CDMO) industries.
- Vesting schedules of four years with quarterly installments are also typical.
- Companies like Catalent, Lonza, and Thermo Fisher Scientific also utilize similar equity-based compensation strategies to incentivize and retain key personnel.
Stakeholder Impact
- The vesting of RSUs and subsequent ownership of common stock aligns the executive's interests with those of shareholders.
- This can positively influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| July 9, 2021 | Date of grant for 696 RSUs vesting quarterly over four years. |
| October 9, 2021 | First vesting date for RSUs granted on July 9, 2021. |
| July 9, 2022 | Date of grant for 1,261 RSUs vesting quarterly over four years. |
| October 9, 2022 | First vesting date for RSUs granted on July 9, 2022. |
| July 9, 2023 | Date of grant for 1,251 RSUs vesting quarterly over four years. |
| October 9, 2023 | First vesting date for RSUs granted on July 9, 2023. |
| April 9, 2024 | Date of RSU conversion to common stock. |
| April 11, 2024 | Date of signature on the Form 4 filing. |
Keywords
Avid Bioservices, CDMO, Mark R. Ziebell, stock options, restricted stock units, RSU, Form 4, insider trading, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.